2011 Arthur Purdy Stout Society Lecture for PathologistsFriday, October 21, 2:00pm-2:50pm
Prospects and Promise for the Practice of Personalized Medicine by Pathologists
The application of molecular techniques to specific disease contexts has dramatically improved our understanding of the pathologic bases for diseases. With the advent of large-scale analytical technologies and informatics capabilities, we have seen an explosion in the amount of knowledge about the genetic bases of diseases and thus the implementation of molecular tests for disease recognition, prognostication, and selection of specific and pathogenetically-relevant therapies. In our role as the central integrators of disease-relevant laboratory testing and reporting, pathologists are now in an excellent position to further contribute real value to patient care.
Kojo S. J. Elenitoba-Johnson, MD, presenter of the 2011 Arthur Purdy Stout Society Lecture for Pathologists, will address the impact and implications of personalized medicine and next-generation technologies on the routine practice of pathology and laboratory medicine. With the proliferation of new genetic and molecular technologies opening new clinical genetic vistas, this presentation is particularly timely.
Dr. Elenitoba-Johnson, is the Henry Clay Bryant Endowed Professor of the Department of Pathology at University of Michigan Medical School, where he also serves as the director of translational pathology and director of the Molecular Diagnostics Laboratory. He received his medical degree from the University of Lagos College of Medicine in Lagos, Nigeria, with subspecialty training in hematopathology at the National Cancer Institute at the National Institutes of Health.
A recipient of many professional awards and honors, he is the recipient of the Ramzi Cotran Outstanding Investigator Award presented by the US and Canadian Academy of Pathology in 2006, and has been selected as the recipient of the 2012 Outstanding Investigator Award presented by the American Society for Investigative Pathology.
Dr. Elenitoba-Johnson and others at the University of Michigan Medical School are working to realize their vision for personalized medicine. Dr. Elenitoba-Johnson’s research is focused on the pathogenesis of human malignant lymphomas, biomarker discovery by genomic and proteomic profiling, and investigation of the role of proteolytic mechanisms in the regulation of critical cellular events and cancer.